Abstract
The sepsis syndrome represents an improper immune response to pathogens and is associated with an unacceptably high rate of mortality. Although supportive care is of benefit to the septic patient, there are no viable therapeutics available that target the immune system suitable for the whole septic population. Recently, using a physiologically relevant murine mouse model, the cannabiniod 2 receptor has been shown to play a critical role in the host response to sepsis. Here, the structure, expression, signaling, and function of the CB2 receptor on leukocytes will be reviewed. Further, the effects mediated by the CB2 receptor during sepsis will be reviewed. Altogether, alterations in inflammation and the host response during sepsis by the CB2 receptor support its use as a possible therapeutic agent.
Keywords: Neutophils, macrophages, T cells, B cells, inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: The Cannabinoid 2 Receptor as a Potential Therapeutic Target for Sepsis
Volume: 10 Issue: 3
Author(s): Kevin Richard Kasten, Johannes Tschop, Matthias Hans Tschop and Charles Curtis Caldwell
Affiliation:
Keywords: Neutophils, macrophages, T cells, B cells, inflammation
Abstract: The sepsis syndrome represents an improper immune response to pathogens and is associated with an unacceptably high rate of mortality. Although supportive care is of benefit to the septic patient, there are no viable therapeutics available that target the immune system suitable for the whole septic population. Recently, using a physiologically relevant murine mouse model, the cannabiniod 2 receptor has been shown to play a critical role in the host response to sepsis. Here, the structure, expression, signaling, and function of the CB2 receptor on leukocytes will be reviewed. Further, the effects mediated by the CB2 receptor during sepsis will be reviewed. Altogether, alterations in inflammation and the host response during sepsis by the CB2 receptor support its use as a possible therapeutic agent.
Export Options
About this article
Cite this article as:
Richard Kasten Kevin, Tschop Johannes, Hans Tschop Matthias and Curtis Caldwell Charles, The Cannabinoid 2 Receptor as a Potential Therapeutic Target for Sepsis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/187153010791936874
DOI https://dx.doi.org/10.2174/187153010791936874 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms Leading to Autoantibody Production: Link Between Inflammation and Autoimmunity
Current Drug Targets - Inflammation & Allergy Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology A Rational Approach on the Use of Sex Steroids in Multiple Sclerosis
Recent Patents on CNS Drug Discovery (Discontinued) Interleukin 10 in Antiviral Responses
Current Immunology Reviews (Discontinued) GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System
Current Pharmaceutical Design Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Neuropeptide Mimetics and Antagonists in the Treatment of Inflammatory Disease: Focus on VIP and PACAP
Current Topics in Medicinal Chemistry Functions of S100 Proteins
Current Molecular Medicine The Role of P-Glycoprotein in Psychiatric Disorders: A Reliable Guard of the Brain?
Central Nervous System Agents in Medicinal Chemistry HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol
Current Drug Targets - Cardiovascular & Hematological Disorders Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors
Current Diabetes Reviews Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Alphavirus Vectors for Gene Therapy Applications
Current Gene Therapy Endogeneous Remyelination: Findings in Human Studies
CNS & Neurological Disorders - Drug Targets Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design Recombinant Salmonella Vaccination Technology and Its Application to Human Bacterial Pathogens
Current Pharmaceutical Biotechnology Mesenchymal Stem Cells Neuronal Differentiation Ability: A Real Perspective for Nervous System Repair?
Current Stem Cell Research & Therapy Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Humanized Cobra Venom Factor: Experimental Therapeutics for Targeted Complement Activation and Complement Depletion
Current Pharmaceutical Design